Understanding and Responding to COVID-19 in Wales: Protocol for a Privacy-protecting Data Platform for Enhanced Epidemiology and Evaluation of Interventions
Overview
Authors
Affiliations
Introduction: The emergence of the novel respiratory SARS-CoV-2 and subsequent COVID-19 pandemic have required rapid assimilation of population-level data to understand and control the spread of infection in the general and vulnerable populations. Rapid analyses are needed to inform policy development and target interventions to at-risk groups to prevent serious health outcomes. We aim to provide an accessible research platform to determine demographic, socioeconomic and clinical risk factors for infection, morbidity and mortality of COVID-19, to measure the impact of COVID-19 on healthcare utilisation and long-term health, and to enable the evaluation of natural experiments of policy interventions.
Methods And Analysis: Two privacy-protecting population-level cohorts have been created and derived from multisourced demographic and healthcare data. The C20 cohort consists of 3.2 million people in Wales on the 1 January 2020 with follow-up until 31 May 2020. The complete cohort dataset will be updated monthly with some individual datasets available daily. The C16 cohort consists of 3 million people in Wales on the 1 January 2016 with follow-up to 31 December 2019. C16 is designed as a counterfactual cohort to provide contextual comparative population data on disease, health service utilisation and mortality. Study outcomes will: (a) characterise the epidemiology of COVID-19, (b) assess socioeconomic and demographic influences on infection and outcomes, (c) measure the impact of COVID-19 on short -term and longer-term population outcomes and (d) undertake studies on the transmission and spatial spread of infection.
Ethics And Dissemination: The Secure Anonymised Information Linkage-independent Information Governance Review Panel has approved this study. The study findings will be presented to policy groups, public meetings, national and international conferences, and published in peer-reviewed journals.
Owen R, van Oppen J, Lyons J, Akbari A, Davies G, Torabi F Euro Surveill. 2024; 29(50).
PMID: 39668763 PMC: 11650509. DOI: 10.2807/1560-7917.ES.2024.29.50.2400085.
Alsallakh M, Adeloye D, Vasileiou E, Sivakumaran S, Akbari A, Lyons R JMIR Public Health Surveill. 2024; 10():e43173.
PMID: 39171430 PMC: 11358661. DOI: 10.2196/43173.
Akbari A, Torabi F, Bedston S, Lowthian E, Abbasizanjani H, Fry R BMJ Open. 2024; 14(8):e077675.
PMID: 39097317 PMC: 11733787. DOI: 10.1136/bmjopen-2023-077675.
Zuiderwijk A, Turk B, Brazier F PLoS One. 2024; 19(2):e0297969.
PMID: 38330007 PMC: 10852342. DOI: 10.1371/journal.pone.0297969.
The cost of implementing the COVID-19 shielding policy in Wales.
Sewell B, Farr A, Akbari A, Carson-Stevens A, Dale J, Edwards A BMC Public Health. 2023; 23(1):2342.
PMID: 38008730 PMC: 10680245. DOI: 10.1186/s12889-023-17169-3.